{"id":745320,"date":"2016-10-09T01:15:00","date_gmt":"2016-10-09T01:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/"},"modified":"2025-11-07T01:25:37","modified_gmt":"2025-11-07T06:25:37","slug":"keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/","title":{"rendered":"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress"},"content":{"rendered":"<p class=\"bwalignc\">       Results from KEYNOTE-010 Include Improved Patient-Reported        Health-Related Quality of Life Outcomes and 18-Month Findings of Overall        Survival and Progression-Free Survival in Previously Treated Patients        Whose Tumors Express PD-L1 (Tumor Proportion Score of One Percent or        More)     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<\/p>\n<p class=\"bwalignl\">\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s<br \/>\n      anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at<br \/>\n      18 months compared to standard of care chemotherapy (docetaxel) in<br \/>\n      patients with metastatic non-small cell lung cancer (NSCLC) previously<br \/>\n      treated with platinum-containing chemotherapy whose tumors expressed<br \/>\n      PD-L1 (tumor proportion score [TPS] of one percent or more), as well as<br \/>\n      patients with high levels of PD-L1 expression (TPS of 50 percent or<br \/>\n      more). These data, from the phase 2\/3 KEYNOTE-010 trial, will be<br \/>\n      presented at the ESMO 2016 Congress, the annual meeting of the European<br \/>\n      Society for Medical Oncology, in Copenhagen<b> <\/b>(Abstract #LBA48).\n    <\/p>\n<p>\n      \u201cThese findings \u2013 which show superior survival with longer follow-up<br \/>\n      across patients with PD-L1 expression (tumor proportion score of one<br \/>\n      percent or more), as well as improved quality of life \u2013 point to<br \/>\n      KEYTRUDA as a durable treatment option for many previously treated<br \/>\n      patients with advanced non-small cell lung cancer,\u201d said Roy S. Herbst,<br \/>\n      M.D., Ph.D., professor of medicine and chief of medical oncology, Yale<br \/>\n      Cancer Center and Smilow Cancer Hospital at Yale New Haven. \u201cThese data<br \/>\n      also reinforce the value of using PD-L1 as a biomarker to identify<br \/>\n      patients who are likely to benefit from KEYTRUDA.\u201d\n    <\/p>\n<p>\n      In additional data at the ESMO 2016 Congress from KEYNOTE-010, an<br \/>\n      analysis of patient-reported health-related quality of life<b> <\/b>outcomes<br \/>\n      showed more patients treated with KEYTRUDA (pembrolizumab) reported<br \/>\n      positive outcomes compared to patients treated with chemotherapy<br \/>\n      (Abstract #1219P).\n    <\/p>\n<p>\n      Separately at the ESMO 2016 Congress, researchers presented an analysis<br \/>\n      of PD-L1 prevalence across three separate studies, including<br \/>\n      KEYNOTE-010. Overall, 66 percent of patients with metastatic NSCLC<br \/>\n      expressed any level of PD-L1, and 28 percent expressed high levels of<br \/>\n      PD-L1 (Abstract #1060P).\n    <\/p>\n<p>\n      \u201cOur research in immuno-oncology continues to show tremendous promise,<br \/>\n      with our goal being to extend the lives of significant numbers of<br \/>\n      patients with non-small cell lung cancer,\u201d said Roger Dansey, M.D.,<br \/>\n      senior vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories. \u201cIn this longer-term analysis<br \/>\n      of KEYNOTE-010, among patients who responded to treatment, four times as<br \/>\n      many patients receiving KEYTRUDA were still alive without disease<br \/>\n      progression compared to docetaxel. It is gratifying to see these results<br \/>\n      continue with additional follow-up.\u201d\n    <\/p>\n<p>\n      Merck has a robust clinical development program for KEYTRUDA in lung<br \/>\n      cancer, with multiple registration-enabling studies currently underway.<br \/>\n      The KEYTRUDA clinical development program includes more than 30 tumor<br \/>\n      types in more than 350 clinical trials, including more than 100 trials<br \/>\n      that combine KEYTRUDA with other cancer treatments.\n    <\/p>\n<p>\n      <b>Efficacy and Safety Findings from KEYNOTE-010 (Abstract #LBA48)<\/b>\n    <\/p>\n<p>\n      KEYNOTE-010 is a global, open-label, randomized, pivotal phase 2\/3 study<br \/>\n      evaluating KEYTRUDA (2 mg\/kg or 10 mg\/kg every three weeks) compared to<br \/>\n      standard of care chemotherapy (docetaxel, 75 mg\/m<sup>2<\/sup>&nbsp;every<br \/>\n      three weeks) in patients with previously treated metastatic NSCLC. The<br \/>\n      primary endpoints were OS and progression-free survival (PFS) and were<br \/>\n      assessed based on patients whose tumors expressed PD-L1 (TPS of one<br \/>\n      percent or more) and high levels of PD-L1 (TPS of 50 percent or more).<br \/>\n      Secondary endpoints included overall response rate (ORR) and duration of<br \/>\n      response. KEYNOTE-010 is the first study of its kind to evaluate the<br \/>\n      potential of an immunotherapy compared to chemotherapy based on<br \/>\n      prospective measurement of PD-L1 expression in patients with metastatic<br \/>\n      NSCLC. As previously announced, the study met its primary objective,<br \/>\n      showing that KEYTRUDA significantly improved OS compared to chemotherapy<br \/>\n      in patients with PD-L1 expression (TPS of one percent or more). Findings<br \/>\n      were similar in patients who received the FDA-approved dose of KEYTRUDA<br \/>\n      (2 mg\/kg every three weeks) and an investigational dose of KEYTRUDA (10<br \/>\n      mg\/kg every three weeks). These data also served as the basis for the<br \/>\n      KEYTRUDA (pembrolizumab) application approval by the European Medicines<br \/>\n      Agency (EMA) in July of this year and are currently under review by the<br \/>\n      U.S. Food and Drug Administration (FDA) for the second-line or greater<br \/>\n      NSCLC treatment setting.\n    <\/p>\n<p>\n      At the ESMO 2016 Congress, data from this study of 1,034 patients<br \/>\n      included six months of additional follow-up, with a median follow-up of<br \/>\n      19.2 months (range, 11.7-29.7), and showed superior outcomes of OS, PFS,<br \/>\n      and ORR with KEYTRUDA compared to docetaxel in patients with PD-L1<br \/>\n      expression (TPS of one percent or more) as well as high levels of PD-L1<br \/>\n      expression (TPS of 50 percent or more) \u2013 with consistency of outcomes<br \/>\n      across KEYTRUDA doses.\n    <\/p>\n<p>\n      In patients with PD-L1 expression (TPS of one percent or more), OS at 18<br \/>\n      months was 37 percent (HR, 0.72 [95% CI, 0.60-0.87]; p=0.0003) with<br \/>\n      KEYTRUDA 2 mg\/kg, 43 percent (HR, 0.60 [95% CI, 0.50-0.73]; p&lt;0.00001)<br \/>\n      with KEYTRUDA 10 mg\/kg, and 24 percent with docetaxel. Among all<br \/>\n      patients, median OS was 10.5 months with KEYTRUDA 2 mg\/kg, 13.6 months<br \/>\n      with KEYTRUDA 10 mg\/kg, and 8.6 months with docetaxel. ORR was 19<br \/>\n      percent (95% CI, 15-23, p=0.00025) with KEYTRUDA 2 mg\/kg, 20 percent<br \/>\n      (95% CI, 16-25, p=0.00004) with KEYTRUDA 10 mg\/kg and 10 percent (95%<br \/>\n      CI, 7-13) with docetaxel. Responses to KEYTRUDA continued to be durable;<br \/>\n      among patients with any level of PD-L1 expression who responded to<br \/>\n      treatment, 60 percent on each of the KEYTRUDA treatment arms were alive,<br \/>\n      progression-free, and had not received additional therapy for their<br \/>\n      disease, compared to 15 percent in the docetaxel treatment arm.\n    <\/p>\n<p>\n      In patients with high levels of PD-L1 expression (TPS of 50 percent or<br \/>\n      more), OS at 18 months was 46 percent (HR, 0.54 [95% CI, 0.39-0.73];<br \/>\n      p=0.00004) with KEYTRUDA 2 mg\/kg, 52 percent with KEYTRUDA 10 mg\/kg (HR,<br \/>\n      0.48 [95% CI, 0.35-0.66]; p&lt;0.00001), and 24 percent with docetaxel. In<br \/>\n      this group, median OS was 15.8 months with KEYTRUDA 2 mg\/kg, 18.8 months<br \/>\n      with KEYTRUDA 10 mg\/kg, and 8.2 months with docetaxel. ORR was 29<br \/>\n      percent (95% CI, 22-38, p&lt;0.00001) with KEYTRUDA 2 mg\/kg, 32 percent<br \/>\n      (95% CI, 24-40, p&lt;0.00001) with KEYTRUDA 10 mg\/kg, and nine percent (95%<br \/>\n      CI, 5-14) with docetaxel. Responses to KEYTRUDA continued to be durable;<br \/>\n      among patients with high levels of PD-L1 expression who responded to<br \/>\n      treatment, 68 and 63 percent on the KEYTRUDA 2 mg\/kg and 10 mg\/kg<br \/>\n      treatment arms, respectively, were alive, progression-free, and had not<br \/>\n      received additional therapy for their disease, compared to 15 percent in<br \/>\n      the docetaxel treatment arm.\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies of KEYTRUDA. Treatment-related adverse<br \/>\n      events remained lower with KEYTRUDA compared to docetaxel. Among the<br \/>\n      total study population, 13, 17, and 36 percent of patients experienced<br \/>\n      Grades 3-5 treatment-related adverse events with KEYTRUDA<br \/>\n      (pembrolizumab) 2 mg\/kg, KEYTRUDA 10 mg\/kg, and docetaxel, respectively.<br \/>\n      Compared with the previous analysis, two additional patients in the<br \/>\n      KEYTRUDA 2 mg\/kg arm and five patients in the KEYTRUDA 10 mg\/kg arm<br \/>\n      experienced immune-mediated adverse events, none of which led to death.<br \/>\n      Grade 3-5 immune-mediated adverse events that occurred in two or more<br \/>\n      patients included pneumonitis (n=14), severe skin toxicities (n=8), and<br \/>\n      colitis (n=4). Additional immune-mediated adverse events observed in at<br \/>\n      least two patients in the KEYTRUDA arms of the study included<br \/>\n      hypothyroidism, hyperthyroidism, pancreatitis, adrenal insufficiency,<br \/>\n      myositis, thyroiditis, hepatitis, hypophysitis, and type 1 diabetes<br \/>\n      mellitus. In this study to date, there have been 10 treatment-related<br \/>\n      adverse events that led to death, two with KEYTRUDA 2 mg\/kg, three with<br \/>\n      KEYTRUDA 10 mg\/kg, and five with docetaxel.\n    <\/p>\n<p>\n      These data will be presented in a poster discussion session on Oct. 9<br \/>\n      from 2:45 \u2013 4:15 p.m. CEST (Abstract #LBA48) (Location: Oslo).\n    <\/p>\n<p>\n      <b>Patient-Reported Outcomes Findings from KEYNOTE-010 (Abstract #1219P)<\/b>\n    <\/p>\n<p>\n      Also reported at the ESMO 2016 Congress were health-related quality of<br \/>\n      life (HRQoL) outcomes from the KEYNOTE-010 trial. Findings were based on<br \/>\n      patient-reported assessments using the European Organization for<br \/>\n      Research and Treatment of Cancer Quality of Life Questionnaire Core 30<br \/>\n      (EORTC QLQ-C30), EORTC QLQ Lung Cancer 13, and EuroQol-5D-3L instruments<br \/>\n      to measure for outcomes such as physical, role, emotional, cognitive,<br \/>\n      and social functioning, as well as lung cancer and treatment-related<br \/>\n      symptoms, among other measures.\n    <\/p>\n<p>\n      Overall, from baseline to the 12-week assessment, patients treated with<br \/>\n      KEYTRUDA (2 mg\/kg or 10 mg\/kg every three weeks) reported numeric<br \/>\n      improvements, some of which were significant, in HRQoL and prolonged<br \/>\n      time to deterioration of lung cancer symptoms (defined using a composite<br \/>\n      endpoint of cough, dyspnea, and chest pain) compared with docetaxel (75<br \/>\n      mg\/m<sup>2<\/sup>&nbsp;every three weeks).\n    <\/p>\n<p>\n      These findings, along with results from additional patient-reported<br \/>\n      outcomes analyses, suggest that HRQoL and symptoms were maintained or<br \/>\n      improved more with KEYTRUDA than with docetaxel.\n    <\/p>\n<p>\n      These data were presented in a poster session on Oct. 8 from 1 \u2013 2 p.m.<br \/>\n      CEST (Location: Hall E).\n    <\/p>\n<p>\n      <b>PD-L1 Prevalence Findings from KEYNOTE-001, -010, and -024 (Abstract<br \/>\n      #1060P)<\/b>\n    <\/p>\n<p>\n      Results from a third NSCLC abstract at the ESMO 2016 Congress explored,<br \/>\n      for the first time, the prevalence of PD-L1 in patients screened across<br \/>\n      multiple studies. The analysis assessed 4,784 patients with NSCLC who<br \/>\n      had tumors evaluable for PD-L1 expression and were screened for<br \/>\n      eligibility in three registrational studies of KEYTRUDA (pembrolizumab)<br \/>\n      \u2013 KEYNOTE-001, KEYNOTE-010, and KEYNOTE-024. Based on this pooled<br \/>\n      analysis, 66 percent of patients across all three trials were determined<br \/>\n      to express PD-L1 (TPS of one percent or more) and 28 percent were<br \/>\n      determined to have high levels of PD-L1 expression (TPS of 50 percent or<br \/>\n      more). These findings were similar across demographic and disease<br \/>\n      characteristics examined, including prior lines of therapy, age, tumor<br \/>\n      source (primary and metastases), and histology (squamous and<br \/>\n      non-squamous).\n    <\/p>\n<p>\n      These data will be presented in a poster session on Oct. 9 from 1 \u2013 2<br \/>\n      p.m. CEST (Location: Hall E).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single use vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a dose of 2 mg\/kg every three weeks.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with metastatic<br \/>\n      non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as<br \/>\n      determined by an FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy, at a dose of 2 mg\/kg every three<br \/>\n      weeks. Patients with EGFR or ALK genomic tumor aberrations should have<br \/>\n      disease progression on FDA-approved therapy for these aberrations prior<br \/>\n      to receiving KEYTRUDA. This indication is approved under accelerated<br \/>\n      approval based on tumor response rate and durability of response. An<br \/>\n      improvement in survival or disease-related symptoms has not yet been<br \/>\n      established. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)<br \/>\n      with disease progression on or after platinum-containing chemotherapy at<br \/>\n      a fixed dose of 200 mg every three weeks. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Immune-mediated pneumonitis occurred in 19 (3.5%) of 550 patients,<br \/>\n      including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%), or 5 (0.2%) pneumonitis<br \/>\n      and occurred more frequently in patients with a history of<br \/>\n      asthma\/chronic obstructive pulmonary disease (5.4%) or prior thoracic<br \/>\n      radiation (6.0%). Monitor patients for signs and symptoms of<br \/>\n      pneumonitis. Evaluate suspected pneumonitis with radiographic imaging.<br \/>\n      Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold<br \/>\n      KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      Immune-mediated colitis occurred in 4 (0.7%) of 550 patients, including<br \/>\n      Grade 2 (0.2%) or 3 (0.4%) colitis. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Immune-mediated hepatitis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 1 (0.2%) of 550 patients, which was Grade 3 in<br \/>\n      severity. Monitor patients for signs and symptoms of hypophysitis<br \/>\n      (including hypopituitarism and adrenal insufficiency). Administer<br \/>\n      corticosteroids and hormone replacement as clinically indicated.<br \/>\n      Withhold KEYTRUDA for Grade 2; withhold or discontinue for Grade 3 or 4<br \/>\n      hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 10 (1.8%) of 550 patients, including Grade 2<br \/>\n      (0.7%) or 3 (0.3%) hyperthyroidism. Hypothyroidism occurred in 38 (6.9%)<br \/>\n      of 550 patients, including Grade 2 (5.5%) or 3 (0.2%) hypothyroidism.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA (pembrolizumab) for Grade 3 or 4<br \/>\n      hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 3<br \/>\n      (0.1%) of 2117 patients. Monitor patients for hyperglycemia or other<br \/>\n      signs and symptoms of diabetes. Administer insulin for type 1 diabetes,<br \/>\n      and withhold KEYTRUDA and administer anti-hyperglycemics in patients<br \/>\n      with severe hyperglycemia.\n    <\/p>\n<p>\n      Immune-mediated nephritis occurred in patients receiving KEYTRUDA.<br \/>\n      Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of 550 patients: rash, vasculitis, hemolytic<br \/>\n      anemia, serum sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Severe and life-threatening infusion-related reactions have been<br \/>\n      reported in 3 (0.1%) of 2117 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 14% of 550<br \/>\n      patients. Serious adverse reactions occurred in 38% of patients. The<br \/>\n      most frequent serious adverse reactions reported in at least 2% of<br \/>\n      patients were pleural effusion, pneumonia, dyspnea, pulmonary embolism,<br \/>\n      and pneumonitis. The most common adverse reactions (reported in at least<br \/>\n      20% of patients) were fatigue (44%), cough (29%), decreased appetite<br \/>\n      (25%), and dyspnea (23%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 350 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=42da7f4de40d3221fa0680e6ca9204e7\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=a69d165e031f6fd6aa075cfbd9787777\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=267417bc5c01f1548d4f0d7bc6cc7378\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=fdbc50ee987f33640e04125668a9ad5f\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=8a07dbd8478893264327eef2079b6fef\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=00964d126b128a819f3da565f0534e18\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=a5c2921e441f85014ed43888d39a63ca\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=858b676bfdd18216896eaa9fb3e47119\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51435698&amp;newsitemid=20161008005057&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=e09c15b5e4bb3f2f60ca8f9a5bc0a7ad\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161008005057r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Courtney        Ronaldo, 908-236-1108<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months compared to standard of care chemotherapy (docetaxel) in patients with metastatic non-small cell lung cancer (NSCLC) previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1 (tumor proportion score [TPS] of one percent or more), as well as patients with high levels of PD-L1 expression (TPS of 50 percent or more). These data, from the phase 2\/3 KEYNOTE-010 trial, will be presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, in Copenhagen (Abstract #LBA48). \u201cThese findings \u2013 which show superior survival with longer follow-up across patients with PD-L1 expression (tumor proportion score of one percent or more), as well as improved quality of life \u2013 point to KEYTRUDA as a durable treatment option for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289,56],"class_list":["post-745320","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months compared to standard of care chemotherapy (docetaxel) in patients with metastatic non-small cell lung cancer (NSCLC) previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1 (tumor proportion score [TPS] of one percent or more), as well as patients with high levels of PD-L1 expression (TPS of 50 percent or more). These data, from the phase 2\/3 KEYNOTE-010 trial, will be presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, in Copenhagen (Abstract #LBA48). \u201cThese findings \u2013 which show superior survival with longer follow-up across patients with PD-L1 expression (tumor proportion score of one percent or more), as well as improved quality of life \u2013 point to KEYTRUDA as a durable treatment option for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\\\/\",\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-09T01:15:00+00:00\",\"dateModified\":\"2025-11-07T06:25:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, demonstrated superiority in overall survival (OS) at 18 months compared to standard of care chemotherapy (docetaxel) in patients with metastatic non-small cell lung cancer (NSCLC) previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1 (tumor proportion score [TPS] of one percent or more), as well as patients with high levels of PD-L1 expression (TPS of 50 percent or more). These data, from the phase 2\/3 KEYNOTE-010 trial, will be presented at the ESMO 2016 Congress, the annual meeting of the European Society for Medical Oncology, in Copenhagen (Abstract #LBA48). \u201cThese findings \u2013 which show superior survival with longer follow-up across patients with PD-L1 expression (tumor proportion score of one percent or more), as well as improved quality of life \u2013 point to KEYTRUDA as a durable treatment option for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:37+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/","name":"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-09T01:15:00+00:00","dateModified":"2025-11-07T06:25:37+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-showed-continued-overall-survival-benefit-compared-to-chemotherapy-with-longer-follow-up-in-patients-with-previously-treated-metastatic-non-small-cell-lung-cancer-in-dat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"KEYTRUDA\u00ae (pembrolizumab) Showed Continued Overall Survival Benefit Compared to Chemotherapy with Longer Follow-Up in Patients with Previously Treated Metastatic Non-Small Cell Lung Cancer in Data to Be Presented at ESMO 2016 Congress"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"ec717979-6541-496a-adf6-b6724abafc3b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/KEYTRUDA-pembrolizumab-Showed-Continued-Overall-Survival-Benefit-Compared-to-Chemotherapy-with-Longer-Follow-Up-in-Patients-with-Prev-JO7J8.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745320\/revisions"}],"predecessor-version":[{"id":3674727,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745320\/revisions\/3674727"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745320"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}